Sector News

Roche buys France’s Trophos in 470 million euro deal

January 16, 2015
Life sciences
Roche has hit the acquisition trail to buy France’s Trophos in a deal that could be worth 470 million euros.
 
Trophos, a privately-held biotech based in Marseille, France, has developed olesoxime, which is being developed for spinal muscular atrophy – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a Phase II trial have shown a beneficial effect on the maintenance of neuromuscular function and a reduction in medical complications associated with the disease.
 
Under the terms of the agreement, Trophos’ shareholders will receive 120 million euros upfront and up to 350 million euros based on achievement of predetermined milestones.
 
Roche’s chief medical officer Sandra Horning said “we will build on the work done by Trophos and the French Muscular Dystrophy Association to advance the development of olesoxime and to bring it to people who live with this devastating condition as quickly as possible”. The compound has orphan drug status on both sides of the Atlantic.
 
The deal rounds off a busy week for Roche, which has paid over $1 billion to acquire a majority stake in molecular information company Foundation Medicine. The Swiss giant licensed an early-stage treatment for antibiotic resistance from Japan’s Meiji Seika Pharma and Fedora of Canada in a deal that could be worth $750 million.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach